Welcome to ViaCyte's JDRF One Walk team page! 2016 marks the ninth year Team ViaCyte has participated in the JDRF One Walk by fundraising and walking in the San Diego event.The steps our team members take on Walk day will support JDRF's highest priority- funding research to deliver a cure for type 1 diabetes and its complications. JDRF is the leading global organization focused on type 1 diabetes (T1D) research, and money raised by our JDRF Walk team will support these costly scientific activities.
In a special tribute for this year, Team ViaCyte has dedicated our walk to Jordan Klein. As the son of Robert Klein, who led the successful Proposition 71 campaign that established the California Institute for Regenerative Medicine (CIRM), Jordan was an important part of our T1D community.
Jordan passed away earlier this year, at the age of 26, from complications related to T1D. We at ViaCyte are extremely saddened by his untimely death. This tragic loss only further shows the urgency of our mission and the importance of not stopping until we can deliver a cure. We walk this year in memory of Jordan and in support of the efforts that seek to one day turn Type One into Type None.
As we walk on behalf of JDRF, ViaCyte is also making strides to transform the lives of people living with diabetes. ViaCyte's primary goal is to develop a product that frees people with type 1 diabetes from long-term insulin-dependence. We are currently investigating our stem cell-derived PEC-Encap (also known as VC-01) product candidate in the STEP ONE clinical trial in the U.S. and Canada. As well, in the past few years we have made significant progress with our PEC-Direct product candidate, which is being developed for high-risk type 1 diabetes patients. We expect to begin clinical testing of this second product in 2017. ViaCyte shares JDRF's focus on developing better treatments that will help people with T1D live healthier lives now and in the future.
ViaCyte and JDRF have maintained a productive alliance for over a decade. ViaCyte was awarded its first research grant from JDRF in 2004. In 2009, JDRF recognized the company for its advances in diabetes research when it named ViaCyte as its Corporate Honoree at the JDRF Promise Ball. We entered into a Research, Development, and Commercialization Agreement in 2011, under which JDRF provided $3 million towards development of the PEC-Encap drug product candidate for the treatment of type 1 diabetes. In 2013, JDRF provided additional funding alongside the California Institute for Regenerative Medicine to support continued development of ViaCyte's cutting-edge therapy, with each group contributing $3 million. Most recently, JDRF committed to milestone-based funding of up to an additional $7 million that has helped ensure rapid transition into our clinical phase of development. The support of JDRF on these projects has been instrumental in assuring their progress and probability of success.
This recognition and the growing momentum of our research and development would not be possible without the support of our talented team and members of our community. We sincerely hope that you will join us to make a difference in the lives of millions of people affected by diabetes. On Walk day, we'll celebrate how much closer we are to a cure- thanks to our community of coworkers, friends, and families.
As our team members are diligently pursuing their fundraising, please consider supporting Team ViaCyte by making a donation or joining our team. To make a team donation, click on the "Donate to this Team" button on this page. To donate your gift to a particular team member, click on the "Donate" button next to his or her name. Finally, to join our team, click the "Join this Team" link on this page.
Thank you. Together, we can turn Type One into Type None!
Your donation will count towards the team's fundraising total. In addition, please give credit to the person that asked for your support to recognize them for their efforts in creating a world without type 1 diabetes (T1D).